Login to Your Account

Raptor glides on promising phase II/III data in Huntington’s

By Marie Powers
Staff Writer

Thursday, February 20, 2014

Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) hit a 52-week high of $17.69 Thursday after the company reported encouraging top-line results from a planned 18-month analysis of an ongoing, three-year phase II/III trial of RP103 (delayed-release cysteamine) in Huntington’s disease (HD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription